Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

Our study provides the longest follow-up of advanced GIST patients treated with regorafenib in this phase II trial. Particular benefit among exon 11 KIT mutations and SDH-deficient GIST were observed. Liberal use of dose reductions and treatment breaks were required to optimize long-term drug exposure.

from Cancer via ola Kala on Inoreader http://ift.tt/29iSVbV
via IFTTT